Cash and Cash Equivalents, Investments and Restricted Cash

The following table shows our cash and cash equivalents, restricted cash and investments’ adjusted cost, unrealized gain (loss) and fair value as of September 30, 2016 and December 31, 2015 (in thousands):



	September 30, 2016						December 31, 2015
	Cost		Net Unrealized Gain/(Loss)		Fair Value		Cost		Net Unrealized Gain/(Loss)			Fair Value
Cash and cash equivalents:
Cash	$	88,935	$	—	$	88,935	$	52,905	$	—		$	52,905
Money market funds	1,278		—		1,278		6,672		—			6,672
Commercial paper	—		—		—		5,453		—			5,453
Corporate securities	—		—		—		600		(1		)	599
Agency bond	—		—		—		1,400		—			1,400
Total cash and cash equivalents	$	90,213	$	—	$	90,213	$	67,030	$	(1	)	$	67,029
Short-term investments:
Commercial paper	$	—	$	—	$	—	$	3,746	$	—		$	3,746
Corporate securities	—		—		—		10,572		(12		)	10,560
Agency bonds	—		—		—		3,494		—			3,494
Total short-term investments	$	—	$	—	$	—	$	17,812	$	(12	)	$	17,800
Long-term investments:
Corporate securities	$	—	$	—	$	—	$	3,241	$	(10	)	$	3,231
Agency bond	—		—		—		1,001		(3		)	998
Long-term corporate securities	$	—	$	—	$	—	$	4,242	$	(13	)	$	4,229

Short-term restricted cash	$	—	$	—	$	—	$	300	$	—		$	300
Long-term restricted cash	84		—		84		478		—			478
Total restricted cash	$	84	$	—	$	84	$	778	$	—		$	778

The amortized cost and fair value of available-for-sale investments as of September 30, 2016 was $1.3 million, respectively, and consist of money market fund deposits which are not due at a single maturity date.

As of September 30, 2016, we did not carry a balance of short-term or long-term investments. Our investment policy generally limits the amount of credit exposure to any one issuer. The policy requires investments generally to be investment grade, with the primary objective of preserving capital and maintaining liquidity. Fair values were determined for each individual security in the investment portfolio. When evaluating an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates and our intent to sell or whether it is more likely than not it will be required to sell, and the investment before recovery of the investment’s cost basis. During the nine months ended September 30, 2016, we did not recognize any impairment charges.

Strategic Investment

During the three months ended September 30, 2016 and 2015, we invested $1.0 million and $2.0 million, respectively, in a third party to expand our customer reach. Our total investment of $3.0 million is included in other assets on our condensed consolidated balance sheet. We did not record other-than-temporary impairment charges on this investment during the three and nine months ended September 30, 2016 and 2015, respectively, as there were no significant identified events or changes in circumstances that would be considered an indicator for impairment.